The incidence and mortality of prostate cancer is highly varied among populations and
especially among blacks and whites. The incidence rates of all American populations have …

BACKGROUND The rapid escalation in the incidence of prostate carcinoma between the
years 1988 and 1992 has been attributed to prostate specific antigen screening. There have …

The increased use of prostate-specific antigen (PSA) in screening for preclinical disease
after 1985 is thought to be a major determinant of the changing patterns in prostate cancer …

BACKGROUND: The prostate-specific antigen test was approved by the US Food and Drug
Administration in 1986 to monitor the disease status in patients with prostate cancer and, in …

BACKGROUND Screening for and the aggressive treatment of prostate carcinoma are
controversial, but they are nevertheless being practiced in the US Current clinical studies of …

Objectives. The use of prostate-specific antigen (PSA) to screen for prostate cancer remains
controversial. Although it is still too early to measure directly the effects of PSA screening on …

Rates of diagnosed prostate cancer have increased substantially in the United States. To
provide clues to the impact of screening and other diagnostic procedures on this increase …

Available epidemiologic data do not allow targeting of specific populations for prostate
cancer screening or early detection programs. Although certain strong factors have been …

Prostate cancer incidence and mortality rates vary worldwide. In the United States, prostate
cancer is the most common malignancy affecting men and is the second-leading cause of …

PURPOSE: We describe trends in prostate cancer mortality from 1980 to 1997, before and
after the introduction of serum prostate specific antigen (PSA) testing to the community …